StockNews.com Downgrades Repligen (NASDAQ:RGEN) to Sell

Repligen (NASDAQ:RGEN - Get Free Report) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued to investors on Thursday.

A number of other equities research analysts have also commented on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday. They set a "hold" rating and a $165.00 price target for the company. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating on the stock. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday. They issued a "hold" rating and a $165.00 price objective on the stock. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and a consensus price target of $185.20.

Repligen Trading Down 0.5 %

NASDAQ RGEN traded down $0.80 during trading on Thursday, hitting $146.54. 519,146 shares of the company's stock traded hands, compared to its average volume of 654,899. The stock has a fifty day moving average of $144.07 and a two-hundred day moving average of $141.81. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The firm has a market cap of $8.21 billion, a P/E ratio of -396.04, a PEG ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. During the same period in the prior year, the business posted $0.23 EPS. Repligen's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, sell-side analysts expect that Repligen will post 1.54 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of RGEN. Andra AP fonden purchased a new position in shares of Repligen during the second quarter valued at approximately $25,000. UMB Bank n.a. raised its stake in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after buying an additional 130 shares during the last quarter. Blue Trust Inc. boosted its holdings in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 127 shares in the last quarter. Resources Management Corp CT ADV purchased a new stake in shares of Repligen in the third quarter worth $37,000. Finally, International Assets Investment Management LLC bought a new position in shares of Repligen during the second quarter valued at $33,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.